← Back to contracts

Evaluating the Effect of a Local Microvascular Tissue Graft Treatment in Rat Models of Diabetic Peripheral Neuropathy

US · IL National Institutes of Health grant awarded #nih-1R43DK142592-01A1

Summary

MicroVascular Tissues, Inc. (MVT) proposes a Phase I SBIR project to conduct preclinical studies in rat models to evaluate the effect of their novel microvascular tissue graft (mVASC) treatment on diabetic peripheral neuropathy (DPN) and sensation.

What they want

The project aims to better understand the preliminary results of mVASC’s effect on DPN and sensation utilizing rigorous and well-accepted research models and assessment tools. mVASC is a novel, human structural allograft consisting of lyophilized and terminally sterilized allogeneic microvascular tissue, designed to serve as a scaffold for cellular invasion and capillary growth, resulting in improved microcirculatory blood flow. The study will investigate mVASC as an injectable treatment to determine whether it directly impacts mild to moderate neuropathy.
Deliverables
  • Preclinical study results on mVASC's effect on DPN and sensation
  • Data to support a Phase II SBIR grant application
Technical requirements
  • Use of rat models of diabetic peripheral neuropathy
  • Rigorous and well-accepted research models and assessment tools
  • Application of mVASC (microvascular tissue graft) as an injectable treatment

Market context

inferred from NAICS
Professional, Scientific & Technical Services
NAICS 541714
US market size
$2.0T
Typical award
$25K – $50M
Typical buyers
All federal civilianDoDStates
Commonly required
8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Evaluating the Effect of a Local Microvasc…
Onboard ↗